title: Epithelial lining fluid neutrophil-gelatinase-associated lipocalin levels in premature newborns with bronchopulmonary dysplasia and patency of ductus arteriosus.
abstract: Patency of the ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD) development represent severe affections for premature newborns, therefore the research of early markers for these two conditions is really important. The aim of this study is to analyze epithelial lining fluid (ELF) Neutrophil-gelatinase-associated lipocalin (NGAL) levels for prediction of lung injury or possible involvement of this molecule in PDA. Only scarce and contrasting results have previously been published in this field. In contrast, this molecule, included in a large macromolecular complex together with matrix metalloproteinase-9 (MMP-9), is considered an acceptable marker of infectious/inflammatory processes, cancer monitoring and induction of apoptotic pathway. NGAL was detected in 28 pre-term newborns by means of a commercially available kit in bronchoalveolar lavage fluid (BALF). The results have been corrected to ELF levels, by the urea method, to eliminate bias due to BALF collection. ELF NGAL levels were found significantly increased both in infants developing BPD or in those affected by PDA. By means of multivariate logistic regression analysis the significances were confirmed after adjusting for possible interfering variables such as gestational age and concomitant presence of both PDA and BPD. Our results stress the involvement of NGAL in the mechanisms leading to BPD and also suggest a possible association with PDA, which is often linked to prematurity and BPD development, probably due to the involvement of inflammatory and angiogenetic processes in both pathologies.
authors.affiliation: Dept. of Biochemistry and Clinical Biochemistry, Policlinico A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy. ecapoluongo@rm.unicatt.it
authors.forename: E
authors.initials: E
authors.lastname: Capoluongo
authors.forename: G
authors.initials: G
authors.lastname: Vento
authors.forename: P
authors.initials: P
authors.lastname: Lulli
authors.forename: E
authors.initials: E
authors.lastname: Di Stasio
authors.forename: S
authors.initials: S
authors.lastname: Porzio
authors.forename: V
authors.initials: V
authors.lastname: Vendettuoli
authors.forename: M
authors.initials: M
authors.lastname: Tana
authors.forename: C
authors.initials: C
authors.lastname: Tirone
authors.forename: C
authors.initials: C
authors.lastname: Romagnoli
authors.forename: C
authors.initials: C
authors.lastname: Zuppi
authors.forename: F
authors.initials: F
authors.lastname: Ameglio
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D015415:Biomarkers; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D001997:Bronchopulmonary Dysplasia / Q000378:metabolism*; D004374:Ductus Arteriosus, Patent / Q000378:metabolism*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D000071068:Lipocalin-2; D054834:Lipocalins / Q000032:analysis*; D016015:Logistic Models; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000032:analysis; D011518:Proto-Oncogene Proteins / Q000032:analysis*
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D020780:Matrix Metalloproteinase 9